OncoSec Medical Inc (ONCS)

0.97
NASDAQ : Health Care
Prev Close 0.98
Day Low/High 0.92 / 0.99
52 Wk Low/High 0.88 / 2.08
Avg Volume 97.90K
Exchange NASDAQ
Shares Outstanding 21.17M
Market Cap 20.74M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP To Board Of Directors

OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP To Board Of Directors

Former Head of Global Research and Development for Merck Serono and Head of Global Medical Affairs of Bristol-Myers Squibb brings biopharma drug development, fundraising and M&A experience to OncoSec

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness At Enhancing Tumor Immunogenicity In Preclinical Tumor Models

Data Presented at Keystone Symposia Conference "Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology"

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

In a 24-week trial of 22 patients, OncoSec saw a 41% response rate

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

OncoSec Granted FDA Fast Track Designation For ImmunoPulse® IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab

Provides Opportunities for Upcoming Phase 2b PISCES Clinical Trial and Future Clinical Development

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

Here's a technical look at how to trade five stocks that are ready to break out and trade higher from current levels.

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.

OncoSec Medical To Present At Needham & Company's 14th Annual Healthcare Conference

OncoSec Medical To Present At Needham & Company's 14th Annual Healthcare Conference

OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at Needham &...

OncoSec Medical CEO Punit Dhillon To Host Live Webinar To Provide Corporate Update And 2015 Outlook

OncoSec Medical CEO Punit Dhillon To Host Live Webinar To Provide Corporate Update And 2015 Outlook

OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it will provide a comprehensive corporate update and Q&A session for investors and the...

OncoSec Medical Announces Six Months Results For Fiscal Year End 2015

OncoSec Medical Announces Six Months Results For Fiscal Year End 2015

OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the six months ended January 31, 2015.

OncoSec Medical To Present At Prominent Scientific And Investment Conferences In March

OncoSec Medical To Present At Prominent Scientific And Investment Conferences In March

OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will present at several high-profile events in March, including the 27 th Annual ROTH...

OncoSec Medical Inc. And Heat Biologics, Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms

OncoSec Medical Inc. And Heat Biologics, Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms

OncoSec Medical Inc. ("OncoSec") (OTCQB: ONCS ), a company developing DNA-based intratumoral cancer immunotherapies, and Heat Biologics, Inc.

OncoSec Medical To Present At Two Events In February

OncoSec Medical To Present At Two Events In February

OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will present at two high-profile scientific and investment conferences in February.

OncoSec Medical Obtains Allowance Of Key Patent Application For Intratumoral Delivery Of Plasmid IL-15

OncoSec Medical Obtains Allowance Of Key Patent Application For Intratumoral Delivery Of Plasmid IL-15

OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announces that the United States Patent and Trademark Office (USPTO) has allowed claims covering a method of treating...

OncoSec Medical Plans To Initiate Pilot Study In Triple Negative Breast Cancer

OncoSec Medical Plans To Initiate Pilot Study In Triple Negative Breast Cancer

OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with Triple Negative Breast Cancer (TNBC).

OncoSec Medical To Present At Three Events In January

OncoSec Medical To Present At Three Events In January

OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at three events in January.

OncoSec Medical Announces New Phase II Trial In Head And Neck Cancer Using ImmunoPulse

OncoSec Medical Announces New Phase II Trial In Head And Neck Cancer Using ImmunoPulse

OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary...